Navigation Links
PTC Therapeutics Receives $2.6 Million in Government Grants
Date:6/15/2009

b>ABOUT ATALUREN (PTC124(TM))

Ataluren is an orally delivered, investigational new drug discovered by PTC Therapeutics. The drug is being developed as a new approach for the treatment of nonsense mutation genetic disorders. Nonsense mutations create a premature stop signal in the mRNA causing the ribosome to terminate translation before a full-length protein is generated. This causes the protein to be truncated and non-functioning. Ataluren is designed to allow the ribosome to continue translation of the mRNA, overriding the premature stop signal and leading to the formation of a functioning protein. Ataluren is a potential therapy for patients with nonsense mutation genetic disorders.

Ataluren has demonstrated proof of concept in Phase 2a clinical trials and is currently in a registration-directed pivotal study with the goal of demonstrating that allowing expression of a critical missing protein will safely provide clinical benefits for patients with nonsense mutation genetic disorders. Ataluren has been generally well tolerated across all clinical studies to date.

The FDA and the European Commission have granted PTC124 (ataluren) orphan drug status for the treatment of DMD and cystic fibrosis due to nonsense mutations. The FDA has also granted PTC124 (ataluren) Subpart E designation for expedited development, evaluation, and marketing.

PTC has an exclusive collaboration with Genzyme Corporation for the development and commercialization of ataluren. PTC Therapeutics will market ataluren in the United States and Canada, while Genzyme will commercialize the product in other regions of the world. The development of ataluren has also been supported by grants from the Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation), FDA's Office of Orphan Products Development, the Muscular Dystrophy Association, the Parent Project Muscular Dystrophy, and the
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... WI (PRWEB) November 23, 2014 ... and supplier of fine chemical ingredients to the ... the launch of its new website, Apiscent.com. , ... of Apiscent Labs, clean design, easy navigation, rotating ... make Apiscent Labs stand out. , ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp was a ... with great people and take risks to achieve success. ... at his extraordinarily courageous attitude when taking on challenges. ... with his death impending—that’s how he continued looking for ... take his life. , Carrying on Sharp’s relentless dream ...
(Date:11/22/2014)... 21, 2014 CannLabs, Inc. ... analytics and scientific testing methodologies relating to cannabis, today ... $750,000 line of credit from an existing stockholder of ... have secured this commitment from one of our existing ... CannLabs. “This capital will help accelerate our planned expansions ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed outperformed 137 ... Summit in San Francisco to take first place in ... Valley investors and technology elites as the premier showcase ... Briteseed to move on to the final phase ... with other elite innovation finalists for a $125,000 cash ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
(Date:11/7/2014)... Researchers led by Dr. Debra Auguste, associate professor, ... at The City College of New York, have ... treatment for one of the most aggressive forms ... (TNBCs) have a high mortality rate owing to ... effective therapeutic options. However, Professor Auguste,s team, discovered ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... bloodhound, Sentry the newest in an elite group ... in demanding and rugged environments has helped scientists ... pioneering seafloor laboratory being planned off Washington and Oregon. ... step in developing an extensive sensor network above and ...
... material on a nano scale how can you see what ... and Biological Sciences research Council (BBSRC) fellow has made a ... scientists. With new research published today (13 August) in ... The School of Pharmacy (University of London) and the University ...
... Sentry, a newly developed robot capable of diving ... the ocean, has been successfully completed by scientists ... (WHOI) and the University of Washington (UW). ... deep-water sites for seafloor instruments that will be ...
Cached Biology News:New robot scouts best locations for components of undersea lab 2New robot scouts best locations for components of undersea lab 3Scientists overcome nanotech hurdle 2Scientists overcome nanotech hurdle 3Robot vehicle surveys deep sea off Pacific Northwest 2Robot vehicle surveys deep sea off Pacific Northwest 3
... Thermal Cycler (MBS) is a ... medium to high throughput PCR. ... latest in satellite block technology, ... control, resulting in a system ...
...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
CQCS kit for etra KR 4i , (other units)....
Biology Products: